Acute Eosinophilic and Neutrophilic Pneumonia following Transarterial Chemoembolization with Drug-Eluting Beads Loaded with Doxorubicin for Hepatocellular Carcinoma: A Case Report.

At an intermediate or advanced stage, i.e. stage B or C, based on the Barcelona Clinic Liver Cancer classification of hepatocellular carcinoma (HCC), transarterial chemoembolization (TACE) may be offered as a treatment of palliative intent. We report the case of a patient suffering from acute respiratory distress syndrome after TACE with drug-eluting beads loaded with doxorubicin for HCC. To our knowledge, this is the first case described where a bronchoalveolar lavage was performed, and where significant levels of alveolar eosinophilia and neutrophilia were evident, attributed to a pulmonary toxicity of doxorubicin following liver chemoembolization. © 2014 S. Karger AG, Basel.

Una estratègia per a les biblioteques acadèmiques del primer quart del segle XXI

L'extensió de l'aplicació de les tecnologies digitals a les comunicacions acadèmiques ha estat tal que ha alterat el model de servei que les biblioteques acadèmiques havien estat oferint durant el darrer segle. Tenint en compte el creixement explosiu del contingut digital en el web, avui en dia no està gaire clar el que hauria de ser una biblioteca acadèmica. Aquest article és un intent de proporcionar a les biblioteques acadèmiques una estratègia per el que queda del primer quart de segle XXI. El model té cinc elements: 1) completar el pas de les col·leccions en paper a les col·leccions en format electrònic; 2) retirar col·leccions patrimonials ("legacy")impreses; 3) redistribuir l'espai de la biblioteca; 4) modificar l’orientació dels instruments, els recursos i els coneixements tècnics de la biblioteca i la informació; 5) traslladar el focus de les col·leccions de l'adquisició de fons a la gestió del contingut. Es tindran en compte cadascun dels elements de l'estratègia i les seves interaccions. Es d'esperar que el resultat proporcioni un mapa útil per les biblioteques acadèmiques i els campus als quals donen servei.

Y-90-Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients

The FIT trial was conducted to evaluate the safety and efficacy of 90Y-ibritumomab tiuxetan (0.4 mCi/kg; maximum dose 32 mCi) when used as consolidation of first complete or partial remission in patients with previously untreated, advanced-stage follicular lymphoma (FL). Patients were randomly assigned to either 90Y-ibritumomab treatment (n = 207) or observation (n = 202) within 3 months (mo) of completing initial induction therapy (chemotherapy only: 86%; rituximab in combination with chemotherapy: 14%). Response status prior to randomization did not differ between the groups: 52% complete response (CR)/CR unconfirmed (CRu) to induction therapy and 48% partial response (PR) in the 90Y-ibritumomab arm vs 53% CR/CRu and 44% PR in the control arm. The primary endpoint was progression-free survival (PFS) of the intent-to-treat (ITT) population. Results from the first extended follow-up after a median of 3.5 years revealed a significant improvement in PFS from the time of randomization with 90Y-ibritumomab consolidation compared with control (36.5 vs 13.3 mo, respectively; P < 0.0001; Morschhauser et al. JCO. 2008; 26:5156-5164). Here we report a median follow-up of 66.2 mo (5.5 years). Five-year PFS was 47% in the 90Y-ibritumomab group and 29% in the control group (hazard ratio (HR) = 0.51, 95% CI 0.39-0.65; P < 0.0001). Median PFS in the 90Y-ibritumomab group was 49 mo vs 14 mo in the control group. In patients achieving a CR/CRu after induction, 5-year PFS was 57% in the 90Y-ibritumomab group, and the median had not yet been reached at 92 months, compared with a 43% 5-year PFS in the control group and a median of 31 mo (HR = 0.61, 95% CI 0.42-0.89). For patients in PR after induction, the 5-year PFS was 38% in the 90Y-ibritumomab group with a median PFS of 30 mo vs 14% in the control group with a median PFS of 6 mo (HR = 0.38, 95% CI 0.27-0.53). Patients who had received rituximab as part of induction treatment had a 5-year PFS of 64% in the 90Y-ibritumomab group and 48% in the control group (HR = 0.66, 95% CI 0.30-1.47). For all patients, time to next treatment (as calculated from the date of randomization) differed significantly between both groups; median not reached at 99 mo in the 90Y-ibritumomab group vs 35 mo in the control group (P < 0.0001). The majority of patients received rituximab-containing regimens when treated after progression (63/82 [77%] in the 90Y-ibritumomab group and 102/122 [84%] in the control group). Overall response rate to second-line treatment was 79% in the 90Y-ibritumomab group (57% CR/CRu and 22% PR) vs 78% in the control arm (59% CR/CRu, 19% PR). Five-year overall survival was not significantly different between the groups; 93% and 89% in the 90Y-ibritumomab and control groups, respectively (P = 0.561). To date, 40 patients have died; 18 in the 90Y-ibritumomab group and 22 in the control group. Secondary malignancies were diagnosed in 16 patients in the 90Y-ibritumomab arm vs 9 patients in the control arm (P = 0.19). There were 6 (3%) cases of myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) in the 90Y-ibritumomab arm vs 1 MDS in the control arm (P = 0.063). In conclusion, this extended follow-up of the FIT trial confirms the benefit of 90Y-ibritumomab consolidation with a nearly 3 year advantage in median PFS. A significant 5-year PFS improvement was confirmed for patients with a CR/CRu or a PR after induction. Effective rescue treatment with rituximab-containing regimens may explain the observed no difference in overall survival between both patient groups who were - for the greater part - rituximab-naïve.

Outcome and Experience from the Swiss Mammography Screening Pilot Programmes

BACKGROUND:The Swiss breast cancer screening pilot programme was conducted in 3 districts of theFrench-speaking canton of Vaud (ca. 300,000 resident women) between October 1993 and January 1999.Women aged 50 to 69 were invited by mail every 2 years for a free of charge screening mammography (doubleview, multiple reading). This first ever-organised cancer screening programme in Switzerland showed thefeasibility and acceptability of this kind of public health intervention in the liberal Swiss healthcare system, whichwas the main objective of the pilot programme. This mammographic screening programme was extended to thewhole canton in 1999, and contributed to the implementation of similar programmes in 2 neighbouring cantons. OBJECTIVE:To appraise the use, the quality and the effectiveness of the Swiss screening pilot programme. METHODS:About 15,000 women (aged 50-69) were enrolled. Logistic regression analyses were performedseparately to identify determinants of initial and subsequent attendance. Standard indicators of quality,effectiveness and impact of the programme were assessed and compared with European recommendations. Tothis intent, linkage with data from the Vaud Cancer Registry was performed. RESULTS:About half the target population was screened at least once during the pilot trial. Participation washigher among Swiss than foreigners, among widowed or married women than among single, divorced or separatedones. Attendance also increased with age and decreasing distance between residence and the dedicatedscreening centre. Apart from Swiss citizenship, socio-demographic factors were not associated with reattendance.Intensity of prior recruitment, outcome of previous screening test (positive vs. negative) and indicators of women'shealth behaviour (time of last mammography prior to initial screen, smoking status) were the main determinants ofreattendance. Programme performance and quality indicators were, overall, in line with European Guidelines. Theywere overall more favourable among 60-69 than 50-59 year-olds and improved over time. CONCLUSION:The objectives of the pilot programme were met. Even if participation should increase in order toreach European standards, performance indicators overall met quality requirements. Ways to improve screeninguse, quality and effectiveness were devised and taken into account for the generalisation of the programme.

Transanal endoscopic microsurgery resection of rectal tumors: outcomes and recommendations.

PURPOSE: Transanal endoscopic microsurgery provides a minimally invasive alternative to radical surgery for excision of benign and malignant rectal tumors. The purpose of this study was to review our experience with transanal endoscopic microsurgery to clarify its role in the treatment of different types of rectal pathology. METHODS: A prospective database documented all patients undergoing transanal endoscopic microsurgery from October 1996 through June 2008. We analyzed patient and operative factors, complications, and tumor recurrence. For recurrence analysis, we excluded patients with fewer than 6 months of follow-up, previous excisions, known metastases at initial presentation, and those who underwent immediate radical resection following transanal endoscopic microsurgery. RESULTS: Two hundred sixty-nine patients underwent transanal endoscopic microsurgery for benign (n = 158) and malignant (n = 111) tumors. Procedure-related complications (21%) included urinary retention (10.8%), fecal incontinence (4.1%), fever (3.8%), suture line dehiscence (1.5%), and bleeding (1.5%). Local recurrence rates for 121 benign and 83 malignant tumors were 5% for adenomas, 9.8% for T1 adenocarcinoma, 23.5% for T2 adenocarcinoma, 100% for T3 adenocarcinoma, and 0% for carcinoid tumors. All 6 (100%) recurrent adenomas were retreated with endoscopic techniques, and 8 of 17 (47%) recurrent adenocarcinomas underwent salvage procedures with curative intent. CONCLUSIONS: Transanal endoscopic microsurgery is a safe and effective method for excision of benign and malignant rectal tumors. Transanal endoscopic microsurgery can be offered for (1) curative resection of benign tumors, carcinoid tumors, and select T1 adenocarcinomas, (2) histopathologic staging in indeterminate cases, and (3) palliative resection in patients medically unfit or unwilling to undergo radical resection.

El desastre quotidià i la disciplina repressora, respostes a la geometria minimal

La proposta de tesi pren com a punt de partida les respostes artístiques i teòriques dutes a terme a partir dels anys seixanta contra un context de coneixement tradicional fonamentalment racionalista, que segueix la tradició lògica de la modernitat i que troba el seu reflex i aplicació social en l’ordre espaial i per extensió, en la geometria. Un cop descrites les nocions que d’aquesta modernitat han estat aplicades a l’art dels anys 50 i 60, es mostra com les crítiques de determinats filòsofs i artistes han anat conformant un corpus teòric i artístic que ha implicat un intent d’enderrocament d’aquest sistema tradicional de coneixement, interpretació, lectura i atorgament de sentit a les obres artístiques. Aquests són: M.Foucault, J.Derrida, R. Smithson, R. Serra, R. Morris, Mona Hatoum, Imi Knoebel o Tacita Dean, entre d’altres. Seguidament es presenta un anàlisi més profund i detallat d’aquelles respostes artístiques més paradigmàtiques, tant al sistema de pensament tradicional com a l’ordre espaial que aquest conseqüentment implica. Aquestes crítiques s’organitzen en dues parts antagòniques: l’una és “L’adveniment del caos”, i l’altra és la “Crítica de l’ordre”. Els artistes són: L. Bourgeois, E.Hesse, A.Mendieta i P.Halley. En una tercera part, es descriu com aquest inici deconstructor del paradigma de coneixement tradicional iniciat als anys seixanta es desenvolupa durant els següents vint anys tenint en aquest cas com a fonament teòric les crítiques de R.Krauss, J. Baudrillard, P.Virilio, i com artistes els arquitectes P. Eienmann i F. Gehri, entre d’altres. La conclusió fonamental d’aquests apartats intenta posar de manifest la subversió o infracció de la geometria com a contenidora dels conceptes de la modernitat: raó i ordre moral. Finalment, en una quarta part s’inclou el propi projecte artístic que representa l’experimentació i praxi de les conclusions teòriques d’aquesta tesi.

Who is the fairest of them all? The independent effect of attractive features and self-perceived attractiveness on cooperation among women

The present paper analyzes the extent to which attractiveness-related variables affect cooperative behavior in women. Cooperativeness is evaluated through a Prisoner's Dilemma Game (PDG). We consider several morphometric variables related to attractiveness: Fluctuating Asymmetry (FA), Waist-Hip Ratio (WHR, Body Mass Index (BMI) and Facial Femininity (FF). These variables have been shown to predict human behavior. We also include as a control variable a score for Self-Perceived Attractiveness (SPA). We test differences in these variables according to behavior in the PDG. Our results reveal that low FA women cooperate less frequently in the PDG. We also find that women with lower WHR are more cooperative. This result contradicts the expected relation between WHR and behavior in the PDG. We show that this effect of WHR on cooperation operates through its influence on the expectation that participants hold on the cooperative intent of their counterpart. In addition, we show that the effect of attractive features on cooperation occurs independently of the participants' perception of their own appeal. Finally, we discuss our results in the context of the evolution of cooperative behavior and under the hypothesis that attractiveness is a reliable indicator of phenotypic quality.

Plasma Level of Mmp-9 as Predictive Factor for Response and Progression Free Survival in Patients Treated with Bevacizumab (Bev) and Pegylated Liposomal Doxorubicin (Pld): Sakk 24/06

Background: There is currently no identified marker predicting benefit from Bev in patients with breast cancer (pts). We monitored prospectively 6 angiogenesis-related factors in the blood of advanced stage pts treated with a combination of Bev and PLD in a phase II trial of the Swiss Group for Clinical Cancer Research, SAKK.Methods: Pts received PLD (20 mg/m2) and Bev (10 mg/kg) every 2 weeks for a maximum of 12 administrations, followed by Bev monotherapy until progression or severe toxicity. Blood samples were collected at baseline, during treatment and at treatment discontinuation. Enzyme-linked immunosorbent assays (Quantikine, R&DSystems and Reliatech) were used to measure vascular endothelial growth factor (VEGF), placental growth factor (PlGF), matrix metalloproteinase 9 (MMP-9) and soluble VEGF receptors -1, -2 and -3. The natural log-transformed (ln) data for each factor was analyzed by analysis of variance (ANOVA) model to investigate differences between the mean values of the subgroups of interest (where a = 0.05), based on the best tumor response by RECIST.Results: 132 samples were collected in 41 pts. The mean of baseline ln MMP-9 levels was significantly lower in pts with tumor progression than those with tumor response (p=0.0202, log fold change=0.8786) or disease control (p=0.0035, log fold change=0.8427). Higher MMP-9 level was a significant predictor of superior progression free survival (PFS): p=0.0417, hazard ratio=0.574, 95% CI=0.336-0.979. In a multivariate cox proportional hazards model, containing performance status, disease free interval, number of tumor sites, visceral involvement and prior adjuvant chemotherapy, using stepwise regression baseline MMP-9 was still a statistically 117P Table 1. SOLTI-0701* AC01B07* NU07B1* SOR+CAP N=20 PL+CAP N=33 SOR+ GEM/CAP N=23 PL+ GEM/CAP N=27 SOR+PAC N=48 PL+PAC N=46 Baseline characteristics Age, median (range), y 49 (32-72) 53 (30-78 54 (32-69) 57 (31-82) 50 (27-80) 52 (23-74) AJCC stage, n (%) IIIB/IIIC 3 (15) 6 (18) 0 (0) 3 (11) 8 (17) 9 (20) IV 17 (85) 27 (82) 23 (100) 24 (89) 40 (83) 37 (80) Metastatic site, n (%) Non-visceral 3 (15) 6 (18) 7 (30) 6 (22) 9 (19) 17 (37) Visceral 17 (85) 27 (82) 16 (70) 21 (78) 39 (81) 29 (63) Prior metastatic chemo, n (%) 8 (40) 15 (45) 21 (91) 25 (93) - - Efficacy PFS, median, mo 4.3 2.5 3.1 2.6 5.6 5.5 HR (95% CI)_ 0.60 (0.31, 1.14) 0.57 (0.30, 1.09) 0.86 (0.50, 1.45) 1-sided P value_ 0.055 0.044 0.281 Overall survival, median, mo 17.5 16.1 Pending 14.7 18.2 HR (95% CI)_ 0.98 (0.50, 1.89) 1.11 (0.64, 1.94) 1-sided P value_ 0.476 0.352 Safety N=20 N=33 N=22 N=27 N=46 N=46 Tx-emergent Grade 3/4, n (%) 15 (75) 16 (48) 20 (91) 17 (63) 36 (78) 16 (35) Grade 3§ hand-foot skin reaction/ syndrome 8 (40) 5 (15) 8 (36) 0 (0) 14 (30) 2 (4) *Efficacy results based on intent-to-treat population and safety results based on safety population (pts who received study drug[s]); _Cox regression within each subgroup; _log-rank test within each subgroup; §maximum toxicity grade for hand-foot skin reaction/syndrome; AJCC, American Joint Committee on Cancer mittedabstractsª The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com Downloaded from annonc.oxfordjournals.org at Bibliotheque Cantonale et Universitaire on June 6, 2011 significant factor (p=0.0266). The results of the other measured factors were presented elsewhere.Conclusions: Higher levels of MMP-9 could predict tumor response and superior PFSin pts treated with a combination of Bev and PLD. These exploratory results justify further investigations of MMP-9 in pts treated with Bev combinations in order to assess its role as a prognostic and predictive factor.Disclosure: K. Zaman: Participation in advisory board of Roche; partial sponsoring ofthe study by Roche (the main sponsor was the Swiss Federation against Cancer (Oncosuisse)). B. Thu¨rlimann: stock of Roche; Research grants from Roche. R. vonMoos: Participant of Advisory Board and Speaker honoraria

Creació d'un media center amb software lliure

Treball de recerca realitzat per un alumne d'ensenyament secundari i guardonat amb un Premi CIRIT per fomentar l'esperit científic del Jovent l'any 2009. L’objectiu d’aquest treball de recerca és la creació d’un dispositiu encarregat de centralitzar totes les necessitats multimèdia de casa nostra i distribuir aquest contingut a tots els terminals de la xarxa local d’una manera senzilla i automatitzada. Aquest dispositiu s’ha dissenyat per estar connectat a una televisió d’alta definició, que permetrà la reproducció i l’organització de tot el nostre multimèdia d’una manera còmoda i fàcil. El media center s’encarrega de gestionar la nostra filmoteca, fototeca, biblioteca musical i sèries de TV de manera transparent i automàtica. A més a més, l’usuari pot accedir a tot el multimèdia emmagatzemat al media center des de qualsevol dispositiu de la xarxa local a través de protocols com CIFS o UPnP, en un intent de replicar el cloud computing a escala local. El dispositiu ha estat dissenyat per a suportar tot tipus de formats i subtítols, assegurant la compatibilitat total amb arxius lliures de DRM. El seu disseny minimalista i silenciós el fa perfecte per a substituir el reproductor de DVD de la sala. Tot això sense oblidar el seu baix consum, de l’ordre d’un 75% inferior al d’un PC convencional.

La première histoire du christianisme (Les Actes des apôtres)

En écrivant à la suite de l'évangile ses Actes d'apôtres, Luc a signé la première histoire du christianisme. Fut-il un bon historien? Pour beaucoup, son oeuvre serait partielle, partiale, imprécise et antijuive. Daniel Marguerat s'insurge contre ce procès injustement intenté à l'auteur des Actes. Il s'attache à montrer comment Luc construit son récit en contraste avec les historiens de l'époque. On saisit ainsi mieux la grande originalité des Actes sur des thèmes aussi cruciaux que l'identité du christianisme entre Jérusalem et Rome, l'image de Dieu, magie et guérisons, le conflit entre juifs et chrétiens, l'énigme de la fin de Paul.

The use and mis-use of some ecological terms and concepts in epidemiology

The article discusses the current use and mis-use of ecological terms and concepts in epidemiological literature, and in special, in works dealing with zoonotic diseases. A selection of examples was taken from papers recently published on the transmission of Chagas' disease by Triatoma sordida. Proper definitions are listed, with the intent of helping non-ecologists to use those terms and concepts correctly.

Conocer, destruir y venerar : significados del cuerpo en Bartolomé de las Casas

Este trabajo tiene como objetivo revelar significados del cuerpo humano en la obra del cronista de Indias Bartolomé de Las Casas, específicamente en tres de sus libros más representativos: Historia de las Indias, Apologética Historia Sumaria y Brevísima relación de la destruición de las Indias. Después de una lectura detallada y de un riguroso análisis se seleccionaron tres cuerpos temáticos que definen a su vez la estructura con la cual se presenta el trabajo: Conocer, Destruir y Venerar. En Conocer se identifica el conocimiento que sobre el cuerpo humano tuvo Bartolomé de Las Casas a partir de las tradiciones escolástica y enciclopédica. Se describen y explican tres temas fundamentales del dominio del fraile: en un primer apartado la relación del cuerpo y el alma y la teoría de los humores o temperamentos; en el siguiente, lo que se entendía por los órganos exteriores e interiores; y en el último, algunos aspectos exteriores (influencia del cielo y de la tierra, alimentación, afecciones temporales y sexuales, edad de los padres a la hora de engendrar, etc.) que se creía influían en la complexión del cuerpo humano. En la descripción de estas temáticas se analiza la forma cómo Bartolomé de Las Casas intentó aplicar este conocimiento a la corporalidad de los indios; ello a su vez se explica en el afán del fraile por defender con los argumentos europeos conocidos y legitimados, a los indios que estaban siendo explotados y destruidos en el proceso de descubrimiento y conquista del Nuevo Mundo. En el capítulo se puede observar cómo en algunas ocasiones los argumentos de Las Casas no se ajustan muy bien a la descripción de la corporalidad del indio. En Destruir los significados del cuerpo que resultan se derivan de dos tipos de de discurso diferentes. El primero es de carácter “denunciador” identificado en Brevísima relación de la destruición de las Indias, en donde sobresale la elección del léxico, el uso de sinónimos, reiteraciones e hipérboles, para enunciar el cuerpo del indio que está siendo destruido. En este apartado se analizan algunas características estilísticas que permiten observar un sentido diferente del cuerpo del indio y del cuerpo humano en general. El segundo tipo de discurso identificado es de carácter “histórico” y proviene de un análisis de Historia de las Indias. A través del seguimiento a la descripción del cuerpo del personaje Alonso de Ojeda, se observa cómo Bartolomé de Las Casas construyó un héroe dentro del relato a partir de la invulnerabilidad que le otorga al cuerpo del personaje. El análisis que se propone en Venerar, tiene en cuenta el carácter religioso con que Bartolomé de Las Casas signó el cuerpo humano en gran parte de su obra. El primer apartado es un análisis del cuerpo que profana; siguiendo tres temas fundamentales (la condena que Las Casas hace de la adoración a Príapo en la Antigüedad, la exposición de la sodomía y la antropofagia) se observa diferentes formas de profanar con el cuerpo condenadas por Bartolomé de Las Casas. El segundo apartado es un análisis de la forma cómo Bartolomé de Las Casas cristianizó en el relato algunos rituales religiosos de los indios, con el fin de acortar la distancia entre éstos y sus lectores (la cultura europea en general), para proponer su aceptación y sugerir a la vez la predisposición “natural” que tenían para ser cristianizados.

RTOG 0525: Exploratory Subset Analysis from a Randomized Phase III Trial Comparing Standard (std) Adjuvant Temozolomide (TMZ) with a Dose-dense (dd) Schedule for Glioblastoma (GBM)

Purpose/Objective(s): RTwith TMZ is the standard for GBM. dd TMZ causes prolongedMGMTdepletion in mononuclear cells and possibly in tumor. The RTOG 0525 trial (ASCO 2011) did not show an advantage from dd TMZ for survival or progression free survival. We conducted exploratory, hypothesis-generating subset analyses to detect possible benefit from dd TMZ.Materials/Methods: Patients were randomized to std (150-200 mg/m2 x 5 d) or dd TMZ (75-100 mg/m2 x 21 d) q 4 weeks for 6- 12 cycles. Eligibility included age.18, KPS$ 60, and. 1 cm2 tissue for prospective MGMTanalysis for stratification. Furtheranalyses were performed for all randomized patients (''intent-to-treat'', ITT), and for all patients starting protocol therapy (SPT). Subset analyses were performed by RPA class (III, IV, V), KPS (90-100, = 50,\50), resection (partial, total), gender (female, male), and neurologic dysfunction (nf = none, minor, moderate).Results: No significant difference was seen for median OS (16.6 vs. 14.9 months), or PFS (5.5 vs. 6.7 months, p = 0.06). MGMT methylation was linked to improved OS (21.2 vs. 14 months, p\0.0001), and PFS (8.7 vs. 5.7 months, p\0.0001). For the ITT (n = 833), there was no OS benefit from dd TMZ in any subset. Two subsets showed a PFS benefit for dd TMZ: RPA class III (6.2 vs. 12.6 months, HR 0.69, p = 0.03) and nf = minor (HR 0.77, p = 0.01). For RPA III, dd dramatically delayed progression, but post-progression dd patients died more quickly than std. A similar pattern for nf = minor was observed. For the SPT group (n = 714) there was neither PFS nor OS benefit for dd TMZ, overall. For RPA class III and nf = minor, there was a PFS benefit for dd TMZ (HR 0.73, p = 0.08; HR 0.77, p = 0.02). For nf = moderate subset, both ITT and SPT, the std arm showed superior OS (14.4 vs. 10.9 months) compared to dd, without improved PFS (HR 1.46, p = 0.03; and HR 1.74, p = 0.01. In terms of methylation status within this subset, there were more methylated patients in the std arm of the ITT subset (n = 159; 32 vs. 24%). For the SPT subset (n = 124), methylation status was similar between arms.Conclusions: This study did not demonstrate improved OS for dd TMZ for any subgroup, but for 2 highly functional subgroups, PFS was significantly increased. These data generate the testable hypothesis that intensive treatment may selectively improve disease control in those most likely able to tolerate dd therapy. Interpretation of this should be considered carefully due to small sample size, the process of multiple observations, and other confounders.Acknowledgment: This project was supported by RTOG grant U10 CA21661, and CCOP grant U10 CA37422 from the National Cancer Institute (NCI).

Appropriateness of colonoscopy in Europe (EPAGE II). Surveillance after polypectomy and after resection of colorectal cancer.

BACKGROUND AND STUDY AIMS: To summarize the published literature on assessment of appropriateness of colonoscopy for surveillance after polypectomy and after curative-intent resection of colorectal cancer (CRC), and report appropriateness criteria developed by an expert panel, the 2008 European Panel on the Appropriateness of Gastrointestinal Endoscopy, EPAGE II. METHODS: A systematic search of guidelines, systematic reviews and primary studies regarding the evaluation and management of surveillance colonoscopy after polypectomy and after resection of CRC was performed. The RAND/UCLA Appropriateness Method was applied to develop appropriateness criteria for colonoscopy for these conditions. RESULTS: Most CRCs arise from adenomatous polyps. The characteristics of removed polyps, especially the distinction between low-risk adenomas (1 or 2, small [< 1 cm], tubular, no high-grade dysplasia) vs. high-risk adenomas (large [> or = 1 cm], multiple [> 3], high-grade dysplasia or villous features), have an impact on advanced adenoma recurrence. Most guidelines recommend a 3-year follow-up colonoscopy for high-risk adenomas and a 5-year colonoscopy for low-risk adenomas. Despite the lack of evidence to support or refute any survival benefit for follow-up colonoscopy after curative-intent CRC resection, surveillance colonoscopy is recommended by most guidelines. The timing of the first surveillance colonoscopy differs. The expert panel considered that 56 % of the clinical indications for colonoscopy for surveillance after polypectomy were appropriate. For surveillance after CRC resection, it considered colonoscopy appropriate 1 year after resection. CONCLUSIONS: Colonoscopy is recommended as a first-choice procedure for surveillance after polypectomy by all published guidelines and by the EPAGE II criteria. Despite the limitations of the published studies, colonoscopy is also recommended by most of the guidelines and by EPAGE II criteria for surveillance after curative-intent CRC resection.

La nación de "los otros". Afrodescendientes porteños y la construcción de la nación argentina a fines del siglo XIX

Investigación producida a partir de una estancia en Buenos Aires en septiembre del 2007. Los procesos de consolidación de las naciones-estado llevan consigo una serie de políticas y prácticas que se focalizan en la construcción del "pueblo". Particularmente, la construcción del estado nacional argentino en el siglo XIX implicó la definición -por parte de los grupos de poder- de un pueblo que cumpliera con las expectativas que se esperaban de una joven nación que se encaminaba hacia la civilización y el progreso, es decir, lo que en esa época se correspondía con un imaginario de pueblo blanco y europeo. Así, se propiciaron políticas de erosión de quienes habitaban en el territorio nacional pero que no cumplían con aquellos mandatos, promoviendo su “invisibilización”. Nosotros trabajamos una de estas comunidades erosionadas de la memoria y de la historia nacional argentina, la comunidad de afrodescendientes de Buenos Aires. El objeto de la investigación que se está llevando a cabo es justamente el análisis de la población afroargentina de Buenos Aires en las últimas décadas del siglo XIX, un momento en que su presencia e historia estaban siendo negadas de los discursos y de las prácticas. Esta investigación de corte histórico-antropológico necesita para su consecución de un trabajo exhaustivo de archivos, objetivo principal de la beca de investigación fuera de Cataluña. Lo que se intentó en el viaje fue encontrar y rescatar fuentes que permitieran entrever las dinámicas de esta comunidad, sus formas de resistir y/o de negociar un estado nacional cada vez más fuerte y que sentaba las bases de lo que debía ser el “pueblo argentino”.